BioNTech SE Enters Purchase Agreement with CureVac N.V.
Ticker: BNTX · Form: 6-K · Filed: Jun 12, 2025 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Jun 12, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement, partnership, biotech
TL;DR
BioNTech inks deal with CureVac on June 12, 2025. Details in joint press release.
AI Summary
On June 12, 2025, BioNTech SE announced a Purchase Agreement with CureVac N.V., also dated June 12, 2025. This agreement was detailed in a joint press release issued by both companies.
Why It Matters
This agreement signifies a strategic partnership or transaction between two key players in the biotechnology sector, potentially impacting their research, development, or manufacturing capabilities.
Risk Assessment
Risk Level: low — The filing is a routine 6-K report announcing a standard business agreement, with no immediate financial or operational risks apparent.
Key Players & Entities
- BioNTech SE (company) — Registrant and party to the agreement
- CureVac N.V. (company) — Party to the agreement
- June 12, 2025 (date) — Date of the Purchase Agreement and press release
FAQ
What is the nature of the Purchase Agreement between BioNTech SE and CureVac N.V.?
The filing does not specify the exact nature of the Purchase Agreement, only that it was entered into on June 12, 2025, and announced via a joint press release.
When was the Purchase Agreement between BioNTech SE and CureVac N.V. finalized?
The Purchase Agreement was dated as of June 12, 2025.
What form is this SEC filing?
This is a Form 6-K report.
What is BioNTech SE's primary business?
BioNTech SE's Standard Industrial Classification is BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836].
Where is BioNTech SE headquartered?
BioNTech SE is headquartered in Mainz, Germany.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on June 12, 2025 regarding BioNTech SE (BNTX).